nach oben

Journal of Endocrinological Investigation

16.05.2024 | Original Article

TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression

verfasst von: C. Zeng, Y. Zhang, C. Lin, W. Liang, J. Chen, Y. Chen, H. Xiao, Y. Li, H. Guan

Erschienen in: Journal of Endocrinological Investigation

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Thyroid cancer has an overwhelming incidence in the population. Thus, there is an urgent need to understand the underlying mechanism of its occurrence and development, which may provide new insights into therapeutic strategies. The role and mechanism of TFCP2L1 in regulating the progression of thyroid cancer remains unclear.

Methods

Public databases and clinical samples were used to detect the expression of TFCP2L1 in cancer and non-cancer tissues. Kaplan–Meier and Cox regression analyses were used to compare the differences in survival probability of the TFCP2L1 highly expressing group and the TFCP2L1 lowly expressing group. Functional assays were used to evaluate the biological effect of TFCP2L1 on thyroid cancer cells. RNA sequencing and enrichment analyses were used to find out pathways that were activated or inactivated by TFCP2L1.

Results

We demonstrated that TFCP2L1 was significantly downregulated in thyroid cancer. Decreased expression of TFCP2L1 was associated with malignant clinicopathological characteristics. Kaplan–Meier and Cox regression analyses indicated that thyroid tumor patients with low TFCP2L1 expression presented shorter disease-free interval and progression-free interval. Additionally, TFCP2L1 expression was positively correlated with thyroid differentiation degree. Overexpression of TFCP2L1 in thyroid cancer cells inhibited cell growth and motility in vitro, and tumorigenicity and metastasis in vivo. Mechanistically, the NF-κB signaling pathway was found inactivated by overexpressing TFCP2L1.

Conclusion

Our results suggest that TFCP2L1 is a tumor suppressor and potential differentiation regulator, and might be a potential therapeutic target in thyroid cancer.

Nur mit Berechtigung zugänglich

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed

Yan T, Qiu W, Song J, Fan Y, Yang Z (2021) ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells. J Mol Endocrinol 66(1):1–10PubMedCrossRef

Liu HQ, Chen Q, Liu BH, Wang JX, Chen C, Sun SR (2023) Blood profiles in the prediction of radioiodine refractory papillary thyroid cancer: a case- control study. J Multidiscip Healthc 16:535–546PubMedPubMedCentralCrossRef

Zheng L M, Li L, He QQ, Wang M, Ma Y H, Zhu J et al (2021) Response to immunotherapy in a patient with anaplastic thyroid cancer A case report. Medicine 100(32).

Jana T, Brodsky S, Barkai N (2021) Speed-specificity trade-offs in the transcription factors search for their genomic binding sites. Trends Genet 37(5):421–432PubMedCrossRef

Bushweller JH (2019) Targeting transcription factors in cancer-from undruggable to reality. Nat Rev Cancer 19(11):611–624PubMedPubMedCentralCrossRef

Bhagwat AS, Vakoc CR (2015) Targeting transcription factors in cancer. Trends Cancer 1(1):53–65PubMedPubMedCentralCrossRef

Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F et al (2022) Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ 29(11):2190–2202PubMedPubMedCentralCrossRef

Kotarba G, Krzywinska E, Grabowska AI, Taracha A, Wilanowski T (2018) TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer Lett 420:72–79PubMedCrossRef

10.

Qiu DB, Ye SD, Ruiz B, Zhou XL, Liu DH, Zhang Q et al (2015) Klf2 and Tfcp2l1, Two Wnt/beta-catenin targets, Act synergistically to induce and maintain naive pluripotency. Stem Cell Rep 5(3):314–322CrossRef

11.

Sun HW, You Y, Guo MM, Wang XH, Zhang Y, Ye S (2018) Tfcp2l1 safeguards the maintenance of human embryonic stem cell self-renewal. J Cell Physiol 233(9):6944–6951PubMedCrossRef

12.

Zhang M, Ji JX, Wang XX, Zhang XB, Zhang Y, Li YT et al (2021) The transcription factor Tfcp2l1 promotes primordial germ cell-like cell specification of pluripotent stem cells. J Biol Chem 297(4).

13.

Heo J, Noh BJ, Lee S, Lee HY, Kim Y, Lim J et al (2020) Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. Embo Mol Med 12(1)

14.

Heo J, Lee J, Nam YJ, Kim Y, Yun H, Lee S et al (2022) The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. Exp Mol Med 54(6):801–811PubMedPubMedCentralCrossRef

15.

Tun H W, Marlow L A, von Roemeling C A, Cooper S J, Kreinest P, Wu K et al (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. Plos One 5(5).

16.

Vokshi B H, Davidson G, Sedehi N T P, Helleux A, Rippinger M, Haller A R et al (2023) SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun 14(1).

17.

Otto B, Streichert T, Wegwitz F, Gevensleben H, Klatschke K, Wagener C et al (2013) Transcription factors link mouse WAP-T mammary tumors with human breast cancer. Int J Cancer 132(6):1311–1322PubMedCrossRef

18.

Yang J, Bergdorf K, Yan C, Luo W, Chen S C, Ayers G D et al (2023) CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. Mol Cancer 22(1).

19.

Li XY, Yang S, Zhao CY, Yang J, Li C, Shen WH et al (2021) CircHACE1 functions as a competitive endogenous RNA to curb differentiated thyroid cancer progression by upregulating Tfcp2L1 through adsorbing miR-346. Endocr J 68(8):1011–1025PubMedCrossRef

20.

Guan H, Guo Y, Liu L, Ye R, Liang W, Li H et al (2018) INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci 8:26PubMedPubMedCentralCrossRef

21.

Chen Y, Li H, Liang W, Guo Y, Peng M, Ke W et al (2021) SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer. J Cell Biochem 122(8):814–826PubMedCrossRef

22.

Li H, Guan H Y, Guo Y, Liang W W, Liu L H, He X Y et al (2018) CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27. Cell Biosci 8.

23.

Zeng C M, Li H, Liang W W, Chen J X, Zhang Y L, Zhang H R et al (2023) Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma. Endocrine.

24.

Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690CrossRef

25.

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN et al (2018) Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173(2):338-354.e15PubMedPubMedCentralCrossRef

26.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126(3):1052–1066PubMedPubMedCentralCrossRef

27.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q et al (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509–W514.

28.

Zhou J, Xu M, Tan J, Zhou L, Dong F, Huang T (2022) MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer. Front Oncol 12:1030590PubMedPubMedCentralCrossRef

29.

He W, Sun Y, Ge J, Wang X, Lin B, Yu S et al (2023) STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front Endocrinol (Lausanne) 14:1076640PubMedCrossRef

30.

Yu P, Qu N, Zhu R, Hu J, Han P, Wu J et al (2023) TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv 9(35):eadg7125PubMedPubMedCentralCrossRef

31.

Jendrzejewski J, Thomas A, Liyanarachchi S, Eiterman A, Tomsic J, He H et al (2015) PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression. J Clin Endocrinol Metab 100(10):E1370–E1377PubMedPubMedCentralCrossRef

32.

Geng QS, Huang T, Li LF, Shen ZB, Xue WH, Zhao J (2021) Over-expression and prognostic significance of FN1, correlating with immune infiltrates in thyroid cancer. Front Med (Lausanne) 8:812278PubMedCrossRef

33.

Li Y, He J, Wang F, Wang X, Yang F, Zhao C et al (2020) Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer. World J Surg Oncol 18(1):181PubMedPubMedCentralCrossRef

34.

Rotondi M, Coperchini F, Latrofa F, Chiovato L (2018) Role of chemokines in thyroid cancer microenvironment: is CXCL8 the main player? Front Endocrinol (Lausanne) 9:314PubMedCrossRef

35.

Lumachi F, Basso SM, Orlando R (2010) Cytokines, thyroid diseases and thyroid cancer. Cytokine 50(3):229–233PubMedCrossRef

36.

Zeng W, Chang H, Ma M, Li Y (2014) CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol 97(1):184–190PubMedCrossRef

37.

Zhang G Q, Xi C, Shen C T, Song H J, Luo Q Y, and Qiu Z L (2023) Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocr Relat Cancer 30(9).

38.

Karin M (2006) Nuclear factor-κB in cancer development and progression. Nature 441(7092):431–436PubMedCrossRef

39.

Taniguchi K, Karin M (2018) NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309–324PubMedCrossRef

40.

Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O et al (2018) NFkappaB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12. Gastroenterology 155(3):880-891.e8PubMedCrossRef

41.

Jiang SH, Zhu LL, Zhang M, Li RK, Yang Q, Yan JY et al (2019) GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut 68(11):1994–2006PubMedCrossRef

42.

Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18(2):99–115PubMedCrossRef

43.

Ma B, Xu W, Wei W, Wen D, Lu Z, Yang S et al (2018) Clinicopathological and survival outcomes of well-differentiated thyroid carcinoma undergoing dedifferentiation: a retrospective study from FUSCC. Int J Endocrinol 2018:2383715PubMedPubMedCentralCrossRef

44.

Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K et al (2019) 2019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 8(5):227–245PubMedPubMedCentralCrossRef

45.

Hou XK, Tian MR, Ning JY, Wang ZY, Guo FL, Zhang W et al (2023) PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause. Int J Biol Sci 19(12):3970–3986PubMedPubMedCentralCrossRef

46.

Zhang X, Ren D, Wu XQ, Lin X, Ye LP, Lin CY et al (2018) miR-1266 contributes to pancreatic cancer progression and chemoresistance by the STAT3 and NF-kappa B signaling pathways. Mol Therapy-Nucleic Acids 11:142–158CrossRef

47.

Ye R Y, Liu D W, Guan H Y, AiErken N, Fang Z, Shi Y W et al (2021) AHNAK2 promotes thyroid carcinoma progression by activating the NF-kappa B pathway. Life Sci 286

48.

Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12(8):695–708PubMedCrossRef

49.

Huang D, Zeng Y, Deng H Y, Fu B D, Ke Y, Luo J Y et al (2022) SYTL5 promotes papillary thyroid carcinoma progression by enhancing activation of the NF-kappa B signaling pathway. Endocrinology 164(1).

50.

Feng L, Wang R, Yang Y F, Shen X X, Shi Q, Lian M et al (2021) KPNA4 regulated by miR-548b-3p promotes the malignant phenotypes of papillary thyroid cancer. Life Sci 265.

51.

Ke S, Pan Q, Wang C, Su Z, Li M, Liu X (2023) NKD2 trigger NF-kappaB signaling pathway and facilitates thyroid cancer cell proliferation. Mol Biotechnol 65(11):1846–1856PubMedPubMedCentralCrossRef

52.

Cardenas-Diaz FL, Liberti DC, Leach JP, Babu A, Barasch J, Shen T et al (2023) Temporal and spatial staging of lung alveolar regeneration is determined by the grainyhead transcription factor Tfcp2l1. Cell Rep 42(5):112451PubMedPubMedCentralCrossRef

53.

Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381(9871):1058–1069PubMedPubMedCentralCrossRef

54.

Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, Bogdanova TI et al (2010) Copy number and gene expression alterations in radiation-induced papillary thyroid carcinoma from chernobyl pediatric patients. Thyroid 20(5):475–487PubMedCrossRef

55.

Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569–580PubMedCrossRef

56.

Guo K, Qian K, Shi Y, Sun T, Wang Z (2021) LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis 12(12):1097PubMedPubMedCentralCrossRef

57.

Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M (2020) Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne) 11:102PubMedCrossRef

Titel: TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression
verfasst von: C. Zeng
Y. Zhang
C. Lin
W. Liang
J. Chen
Y. Chen
H. Xiao
Y. Li
H. Guan
Publikationsdatum: 16.05.2024
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02392-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin